International Journal of Trichology International Journal of Trichology
 Print this page Email this page Small font sizeDefault font sizeIncrease font size
 
 
  Home | About IJT | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Online submission | Subscribe | Advertise | Contact us | Login   
 


 
 Table of Contents  
LETTER TO EDITOR
Year : 2012  |  Volume : 4  |  Issue : 1  |  Page : 52-53  

Measuring the efficacy of antiretroviral therapy


Department of Internal Medicine, AMC, Medwin Hospital, Hyderabad, Andhra Pradesh, India

Date of Web Publication12-May-2012

Correspondence Address:
Dilip Gude
Registrar, Internal Medicine, AMC, 3rd Floor, Medwin Hospital, Chirag Ali Lane, Nampally, Hyderabad - 500 001, Andhra Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0974-7753.96103

Rights and Permissions

How to cite this article:
Gude D. Measuring the efficacy of antiretroviral therapy. Int J Trichol 2012;4:52-3

How to cite this URL:
Gude D. Measuring the efficacy of antiretroviral therapy. Int J Trichol [serial online] 2012 [cited 2019 Nov 15];4:52-3. Available from: http://www.ijtrichology.com/text.asp?2012/4/1/52/96103

Sir,

Hair levels of antiretroviral therapy (ART) are inexpensive, easy-to-collect biomarkers of pre-exposure prophylaxis (PrEP) as well as treatment reflecting average levels over extended periods of time. They can also integrate adherence and pharmacokinetics into a single assay. The regimen durability can be prolonged based on hair antiretroviral concentrations. Interventions can be planned based on low antiretroviral exposure in hair prior to virologic failure in settings where measurement of viral loads is unavailable.

Tenofovir (TFV) levels in scalp hair demonstrate a clear and consistent correlation with dose. Hair is a promising biomarker of TFV dosing/PrEP and has feasibility advantages over other methods. In a study, 15 Human immune deficiency virus (HIV)-uninfected, dark-haired men and women at low risk for HIV infection received modified directly observed dosing of TFV 300 mg for 2, 4, and 7 doses/week in random order. A log-linear relationship was seen between doses per week and TFV hair level, with a 65% increase in hair level per 2-fold dose increase. [1]

A study on hair samples of participants in the Women's Interagency HIV Study (WIHS) analyzed atazanavir (ATV) hair concentrations longitudinally for women receiving ATV-based therapy. After adjusting for age, race, treatment experience, pretreatment viral load, cluster of differentiation 4 count and AIDS status, and self-reported adherence, hair levels were the strongest predictor of suppression. Categorized hair ATV levels revealed a monotonic relationship to suppression. Hair ATV concentrations were even more strongly associated than serum levels with re-suppression of viral loads in subgroups in which there had been previous lapses in adherence, low hair levels, or detectable viremia. [2] WIHS also studied the association between hair protease inhibitor (PI) levels (lopinavir (LPV) and ATV) and initial virologic responses to therapy. They showed that LPV and ATV concentrations in hair were strongly and independently associated with treatment response in those starting a new PI-based regimen. [3]

A cross-sectional survey studied LPV hair and plasma levels to investigate the etiology of virologic failure in two public health antiretroviral clinics that documented the prevalence of virologic failure and genotypic antiretroviral resistance. A threshold hair concentration indicating longer term LPV exposure was instrumental in determining the etiology of virologic failure and identifying patients in need of adherence counseling or resistance testing. [4] In another study on 43 HIV-infected patients, significant association was found between HIV - ribonucleic acid below 50 copies/ml and indinavir concentrations in hair but not in plasma. [5]

A specific, sensitive, and reproducible liquid chromatography-tandem mass spectrometry method for measuring nevirapine (NVP) levels in human hair (as small as a single short strand of hair) was developed and successfully applied to analyze more than 1000 hair samples. Great extraction efficiencies (>95%) were noted when repeated extractions were done. Deuterated NVP-d5 was used as an internal standard. The accuracies for spiked NVP hair control samples were 98% to 106% with coefficients of variation less than 10%. [6]

The noninvasive nature and the ease of collecting and storing samples make hair analysis an ideal way to determine ART exposure, especially in the epidemic of HIV in resource-poor settings.

 
   References Top

1.Liu A, Gandhi M, Bacchetti P, Huang Y, Anderson P, Goggin K, et al. Validating hair as a biological marker of tenofovir drug exposure in HIV pre-exposure prophylaxis (PrEP). 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 2011.  Back to cited text no. 1
    
2.Gandhi M, Ameli N, Bacchetti P, Anastos K, Gange SJ, Minkoff H, et al. Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis 2011;52:1267-75.  Back to cited text no. 2
[PUBMED]  [FULLTEXT]  
3.Gandhi M, Ameli N, Bacchetti P, Gange SJ, Anastos K, Levine A, et al. Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS 2009;23:471-8.  Back to cited text no. 3
[PUBMED]  [FULLTEXT]  
4.van Zyl GU, van Mens TE, McIlleron H, Zeier M, Nachega JB, Decloedt E, et al. Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. J Acquir Immune Defic Syndr 2011;56:333-9.  Back to cited text no. 4
[PUBMED]  [FULLTEXT]  
5.Duval X, Peytavin G, Breton G, Ecobichon JL, Descamps D, Thabut G, et al. Hair versus plasma concentrations as indicator of indinavir exposure in HIV-1-infected patients treated with indinavir/ritonavir combination. AIDS 2007;21:106-8.  Back to cited text no. 5
[PUBMED]    
6.Huang Y, Yang Q, Yoon K, Lei Y, Shi R, Gee W, et al. Microanalysis of the antiretroviral nevirapine in human hair from HIV-infected patients by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 2011;401:1923-33.  Back to cited text no. 6
[PUBMED]  [FULLTEXT]  




 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References

 Article Access Statistics
    Viewed1451    
    Printed30    
    Emailed0    
    PDF Downloaded35    
    Comments [Add]    

Recommend this journal